Loading organizations...

§ Private Profile · 321 Harrison Ave Ste 600, Boston, MA 02118, United States
Magnet Biomedicine is a technology company.
Magnet Biomedicine is a biotechnology company focused on discovering and developing molecular glues to advance precision medicine. The company employs a proprietary TrueGlue discovery platform, which enables a rational approach to identifying and optimizing these small molecules. Their technology aims to modulate protein-protein interactions within the cell, addressing previously undruggable targets with high specificity and efficacy.
The company was founded by a distinguished group of scientific leaders, including molecular glue researcher Stuart Schreiber, Ph.D., 2017 Nobel Laureate Michael Rosbash, Ph.D., chemical biologists Benjamin Cravatt, Ph.D., and David Spiegel, Ph.D., and geneticist Richa Saxena, Ph.D. This interdisciplinary team formed Magnet with the insight that a systematic and rational framework could unlock the full therapeutic potential of molecular glues, moving beyond serendipitous discoveries. Tom Miller serves as a co-founder and Chief Executive Officer.
Magnet Biomedicine targets the development of novel therapeutic modalities for a range of diseases. Their vision centers on exploiting the unique mechanism of molecular glues to create highly targeted treatments, offering new hope for patients by precisely intervening in disease pathways. The company is committed to pioneering a new class of medicines that expand the druggable landscape and transform patient care.
Magnet Biomedicine has raised $50.0M across 1 funding round.
Magnet Biomedicine has raised $50.0M in total across 1 funding round.
Magnet Biomedicine is a privately held biotechnology company that develops small‑molecule *molecular glue* therapeutics using its proprietary TrueGlue™ discovery platform to induce novel protein‑protein interactions for precision treatment of cancer and immune disorders[2][3].
High-Level Overview
Magnet Biomedicine’s mission is to advance precision medicine by systematically discovering and designing molecular glues that create therapeutic protein‑protein interactions to address difficult‑to‑drug targets in oncology and immune diseases[2][3]. The company’s investment‑style description (if viewed as a tech/biotech “platform” company) is an R&D‑driven, platform‑first approach: it builds a modular discovery engine (TrueGlue™) plus bespoke chemical libraries and screening workflows to generate multiple therapeutic programs rather than a single molecule[2][4]. Key sectors are drug discovery and development with primary focus on oncology and immune disorders[2][4]. Magnet’s activity—especially partnerships with large pharma—has accelerated the molecular‑glue field by demonstrating a scalable route from platform discovery to partnered development and potential commercialization, increasing industry attention and venture/pharma investment into the modality[3][4].
Origin Story
Magnet Biomedicine was founded in 2019 and is headquartered in Boston with research and development presence across multiple sites as its operations have expanded[1][4]. The company was built by scientists and drug‑discovery leaders (leadership publicly lists Brian Safina, Ph.D., as President & CEO)[2]. The idea grew from recognition that *molecular glues*—small molecules that induce or stabilize protein‑protein interactions—are a powerful but underexploited modality, and that a rational, modular discovery platform could expand the range of usable presenter proteins beyond classical E3 ligases to unlock new mechanisms of action[2][4]. Early pivotal moments include development of the TrueGlue™ platform and securing high‑profile collaborations and licensing deals (notably a 2025 collaboration and license with Eli Lilly that included up to $40M upfront plus an equity investment and >$1.25B in potential milestones and royalties)[3].
Core Differentiators
Role in the Broader Tech / Biotech Landscape
Quick Take & Future Outlook
If you want, I can: provide a brief profile of Magnet’s leadership team and board; list public disclosures and filings related to the Lilly deal; or map Magnet’s public pipeline programs and their therapeutic targets with cited source details.
Magnet Biomedicine has raised $50.0M in total across 1 funding round.
Magnet Biomedicine's investors include ARCH Venture Partners, Thomas Cahill, F-Prime Capital Partners, Mubadala.
Magnet Biomedicine has raised $50.0M across 1 funding round. Most recently, it raised $50.0M Series A in September 2023.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Sep 1, 2023 | $50M Series A | ARCH Venture Partners, Thomas Cahill | F Prime Capital, Mubadala | Announced |